Literature DB >> 15386660

Using multilevel models for assessing the variability of multinational resource use and cost data.

Richard Grieve1, Richard Nixon, Simon G Thompson, Charles Normand.   

Abstract

Multinational economic evaluations often calculate a single measure of cost-effectiveness using cost data pooled across several countries. To assess the validity of pooling international cost data the reasons for cost variation across countries need to be assessed. Previously, ordinary least-squares (OLS) regression models have been used to identify factors associated with variability in resource use and total costs. However, multilevel models (MLMs), which accommodate the hierarchical structure of the data, may be more appropriate. This paper compares these different techniques using a multinational dataset comprising case-mix, resource use and cost data on 1300 stroke admissions from 13 centres in 11 European countries. OLS and MLMs were used to estimate the effect of patient and centre-level covariates on the total length of hospital stay (LOS) and total cost. MLMs with normal and gamma distributions for the data within centres were compared. The results from the OLS model showed that both patient and centre-level covariates were associated with LOS and total cost. The estimates from the MLMs showed that none of the centre-level characteristics were associated with LOS, and the level of spending on health was the centre-level variable most highly associated with total cost. We conclude that using OLS models for assessing international variation can lead to incorrect inferences, and that MLMs are more appropriate for assessing why resource use and costs vary across centres. Copyright (c) 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2005        PMID: 15386660     DOI: 10.1002/hec.916

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  23 in total

1.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina.

Authors:  Federico Augustovski; Martín Chaparro; Alfredo Palacios; Lizheng Shi; Andrea Beratarrechea; Vilma Irazola; Adolfo Rubinstein; Katherine Mills; Jiang He; Andrés Pichon Riviere
Journal:  Value Health       Date:  2018-08-30       Impact factor: 5.725

Review 3.  Analysis sans frontières: can we ever make economic evaluations generalisable across jurisdictions?

Authors:  Mark J Sculpher; Michael F Drummond
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Better analysis for better decisions: has pharmacoeconomics come of age?

Authors:  Michael Drummond; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 5.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data.

Authors:  Andrea Manca; Andrew R Willan
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  The generalisability of pharmacoeconomic studies: issues and challenges ahead.

Authors:  James M Mason; Anne R Mason
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis.

Authors:  Hege Urdahl; Andrea Manca; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Bayesian modelling of healthcare resource use in multinational randomized clinical trials.

Authors:  Aline Gauthier; Andrea Manca; Susan Anton
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

9.  Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.

Authors:  Andrea Manca; Paul C Lambert; Mark Sculpher; Nigel Rice
Journal:  Med Decis Making       Date:  2007-07-19       Impact factor: 2.583

10.  A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Authors:  Maureen P M H Rutten-van Mölken; Floortje E van Nooten; Marion Lindemann; Manfred Caeser; Peter M A Calverley
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.